Orris

angiosarcoma

Reading File
Finding Sources
Searching PubMed

angiosarcoma

Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Finding Sources
I now have comprehensive material from multiple authoritative textbooks plus histology images. Let me compile the full answer.

Angiosarcoma

Definition

Angiosarcoma is a malignant neoplasm arising from the endothelial lining of blood (or lymphatic) vessels. It is one of the most aggressive soft-tissue sarcomas (STS), accounting for approximately 2% of all STS. Histology ranges from well-differentiated tumors that mimic hemangiomas to profoundly anaplastic, poorly differentiated lesions.
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 493
  • Sabiston Textbook of Surgery, 14e

Epidemiology

  • Peak incidence in the 7th and 8th decades; older adults predominate
  • Male:female ratio ~2:1 for cutaneous head-and-neck form
  • Most common sites (decreasing order): skin > soft tissue > breast > liver > spleen
  • ~20% of patients present with distant metastasis at diagnosis
  • ~40% of all angiosarcomas are radiation-associated

Pathogenesis and Risk Factors

Angiosarcoma arises in four distinct clinical settings:
SettingKey Feature
Sporadic (de novo)Head/neck skin in elderly men; most common type
Chronic lymphedemaPost-mastectomy upper arm - "Stewart-Treves syndrome"; occurs ~11-12 years post-surgery in ~0.45% of patients; 5-year survival 6-14%
Post-irradiationLatency ~23 years (benign condition) or ~12 years (prior malignancy)
Chemical/hepaticArsenic, Thorotrast (radioactive contrast agent), polyvinyl chloride - all classic hepatic angiosarcoma carcinogens with long latency

Molecular Biology

  • MYC amplification is the molecular hallmark of secondary (post-radiation and post-lymphedema) angiosarcoma - it is absent in primary cutaneous angiosarcoma and in atypical vascular lesions (AVL), making it a key discriminator
  • KDR (VEGFR2) activating mutations have been identified in human angiosarcomas
  • High Ki-67 proliferation index is characteristic

Pathology

Gross

  • Ill-defined, dark-brown/hemorrhagic mass; often multifocal
  • In the heart/right ventricle: appears as a large, dark, infiltrating mass (see image A below)

Histology

Angiosarcoma - Gross and Histology (Robbins). A: Angiosarcoma involving the right ventricle; B: Atypical cells lining vascular lumens (H&E); C: CD31 immunostaining confirming endothelial origin.
Fig. 11.32 - Robbins, Cotran & Kumar Pathologic Basis of Disease
  • Well-differentiated: irregular vascular channels in dermis lined by atypical endothelial cells with enlarged, pleomorphic nuclei
  • Poorly differentiated: solid sheets of epithelioid cells, increased cellularity, nuclear atypia, high mitotic activity; subtle infiltration between collagen bundles producing "crack-like" spaces with hyperchromatic nuclei
Angiosarcoma H&E (Fitzpatrick's). Atypical endothelial cells proliferating in the dermis with irregular vascular spaces.
Fitzpatrick's Dermatology

Immunohistochemistry (IHC)

The following markers confirm endothelial origin:
  • CD31 - most consistent and specific
  • CD34
  • FLI-1 (transcription factor)
  • ERG (endothelial transcription factor)
  • Podoplanin (D2-40) - positive in most malignant vascular tumors
  • Ulex europaeus lectin
  • c-MYC nuclear staining - helps distinguish radiation-induced angiosarcoma from AVL

Clinical Presentation

Cutaneous (Head/Neck - most common)

  • Poorly defined bluish macule on the scalp/face of elderly men - easily mistaken for a bruise
  • Distinguishing features: peripheral erythematous ring, satellite nodules, spontaneous bleeding, intratumoral hemorrhage
  • Progressive asymmetric enlargement with indurated bluish nodules/plaques
  • Sudden thrombocytopenia may herald metastasis or rapid tumor expansion
  • Multicentricity and early metastasis are hallmarks; most patients die within 2 years
  • Prognosis worse in men >70

Stewart-Treves Syndrome

  • Angiosarcoma in chronic lymphedematous upper arm after mastectomy
  • Mean survival 19-31 months; 5-year survival ~6-14%
  • Lung metastases are the most frequent cause of death
  • Early amputation offers the best prognosis

Spread and Prognosis

  • Locally invasive with early hematogenous metastasis
  • Lung is the most common metastatic site; breast angiosarcoma may spread to liver
  • Overall 5-year survival: 10-30% (Robbins)
  • 5-year disease-specific survival for resectable disease: ~53% (Sabiston)
  • Stage IV median survival: 8-12 months

Management

Surgery

  • Wide resection with negative margins (at least 2 cm of normal tissue) is the mainstay
  • Tumors microscopically extend well beyond gross margins
  • Radiation-associated breast angiosarcoma: mastectomy including all irradiated skin (vs. simple mastectomy - dramatically reduces local recurrence from 76% to 23% and improves 5-year DSS from 46% to 86%)
  • Stewart-Treves: amputation

Radiation Therapy

  • Adjuvant radiotherapy for head/neck and scalp angiosarcomas (high locoregional recurrence)
  • Cannot use for radiation-induced tumors

Systemic Therapy (Palliative/Metastatic)

AgentNotes
PaclitaxelFirst-line palliative for cutaneous angiosarcoma; ~56% objective response rate
Doxorubicin ± ifosfamideStandard chemotherapy; modest response rate
PazopanibFor taxane-resistant disease; controls progression especially in cutaneous angiosarcoma
SirolimusShows promise for scalp/facial angiosarcomas
Interferon (IFN)Shows promise for scalp/facial angiosarcomas

Key Points to Remember

  1. Malignant endothelial neoplasm - arises from blood/lymphatic vessel endothelium
  2. Four clinical settings: sporadic head/neck, Stewart-Treves (lymphedema), post-irradiation, chemical (hepatic)
  3. MYC amplification = molecular hallmark of secondary (radiation/lymphedema-associated) angiosarcoma
  4. IHC: CD31 + CD34 + FLI-1 + ERG (confirm endothelial origin); c-MYC distinguishes radiation-induced from AVL
  5. Paclitaxel is first-line systemic therapy; doxorubicin and pazopanib are alternatives
  6. Overall poor prognosis: 5-year survival 10-30%; stage IV median survival 8-12 months
  7. Wide surgical margins critical - tumors extend microscopically well beyond gross disease
Recent Literature: A 2025 systematic review (PMID 40666093) in Frontiers in Oncology reviewed biomarkers in angiosarcoma diagnosis, prognosis, and therapeutics - consistent with the molecular data above. No major updates contradict current textbook guidance.
Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease | Sabiston Textbook of Surgery, 14e | Andrews' Diseases of the Skin, 12e | Fitzpatrick's Dermatology, 9e
This is a shared conversation. Sign in to Orris to start your own chat.